Goldman Sachs’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-300
| Closed | -$20K | – | 6092 |
|
|
2018
Q1 | $20K | Sell |
300
-1,622
| -84% | -$115K | ﹤0.01% | 5675 |
|
|
2017
Q4 | $140K | Sell |
1,922
-7,556
| -80% | -$625K | ﹤0.01% | 5597 |
|
|
2017
Q3 | $868K | Sell |
9,478
-1,466
| -13% | -$112K | ﹤0.01% | 4702 |
|
|
2017
Q2 | $724K | Buy |
10,944
+1,300
| +13% | +$161K | ﹤0.01% | 4751 |
|
|
2017
Q1 | $2.09M | Buy |
9,644
+4,377
| +83% | +$625K | ﹤0.01% | 3701 |
|
|
2016
Q4 | $487K | Sell |
5,267
-1,644
| -24% | -$185K | ﹤0.01% | 5087 |
|
|
2016
Q3 | $934K | Sell |
6,911
-3,333
| -33% | -$331K | ﹤0.01% | 4469 |
|
|
2016
Q2 | $1.04M | Sell |
10,244
-2,678
| -21% | -$332K | ﹤0.01% | 4154 |
|
|
2016
Q1 | $2.12M | Buy |
12,922
+6,989
| +118% | +$1.42M | ﹤0.01% | 3419 |
|
|
2015
Q4 | $1.94M | Sell |
5,933
-2,867
| -33% | -$933K | ﹤0.01% | 3654 |
|
|
2015
Q3 | $2.84M | Buy |
8,800
+233
| +3% | +$102K | ﹤0.01% | 3429 |
|
|
2015
Q2 | $3.41M | Buy |
8,567
+3,989
| +87% | +$1.69M | ﹤0.01% | 3307 |
|
|
2015
Q1 | $2.25M | Sell |
4,578
-14,355
| -76% | -$5.56M | ﹤0.01% | 3664 |
|
|
2014
Q4 | $6.77M | Sell |
18,933
-2,567
| -12% | -$764K | ﹤0.01% | 2697 |
|
|
2014
Q3 | $4.14M | Buy |
21,500
+18,744
| +680% | +$4.12M | ﹤0.01% | 3195 |
|
|
2014
Q2 | $658K | Sell |
2,756
-10,755
| -80% | -$2.19M | ﹤0.01% | 5081 |
|
|
2014
Q1 | $3.45M | Sell |
13,511
-16,289
| -55% | -$4.98M | ﹤0.01% | 3444 |
|
|
2013
Q4 | $5.9M | Buy |
29,800
+10,678
| +56% | +$1.9M | ﹤0.01% | 2893 |
|
|
2013
Q3 | $3.23M | Sell |
19,122
-5,278
| -22% | -$849K | ﹤0.01% | 3417 |
|
|
2013
Q2 | $4.33M | Buy |
+24,400
| New | +$3.46M | ﹤0.01% | 2892 |
|
Goldman Sachs's LUMO Position: Q4 2024 in Review
Goldman Sachs sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 362,198 shares — an estimated $1.4M sold.
Goldman Sachs first reported a position in LUMO in Q2 2013 and held it in 37 quarters. The position peaked at $5.44M in Q1 2017. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- Goldman Sachs reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Goldman Sachs sold 362,198 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $1.4M.
- Goldman Sachs first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 37 quarters.
- Goldman Sachs's Lumos Pharma, Inc. Common Stock position peaked at $5.44M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.